<DOC>
	<DOCNO>NCT01426906</DOCNO>
	<brief_summary>A Randomized , Open Label , Drug-Drug interaction study investigate effect ketoconazole rifampicin Pharmacokinetic characteristic safety LC15-0444 Healthy Male Volunteers .</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Study Healthy Male Subjects</brief_title>
	<detailed_description>This study randomize , open-label , 2-period , 3-treatment , 1-sequence , drug-drug interaction study healthy volunteer evaluate effect ketoconazole rifampicin PK characteristic safety LC15-0444 . Eligibility participation study determine demographic information , medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test within 4 week ( -28 ~ -2 ) first drug administration ( 1 ) . Eligible subject randomize one study treatment group . According characteristic anti-diabetic drug , expect administer drug many patient . Therefore , Drug-Drug Interaction CYP3A4 inducer inhibitor identify trial .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Is healthy male 20 50 year old Has BMI result 19 26 kg/m2 screening ; total body weight 55 kg . BMI ( kg/m2 ) = body weight ( kg ) / { height ( ) } 2 . Is willing able comply schedule visit , treatment plan , laboratory test , study procedure Agrees use adequate mean contraception clinical trial Subjects evidence history clinically significant hepatic , renal , digestive , neurologic , pulmonary , musculoskeletal , endocrine , hematological , cardiovascular psychiatric disease Subjects evidence history gastrointestinal disease surgery possibly affect drug absorption . Subjects history hypersensitivity clinically significant adverse event cause DPPIV inhibitor , ketoconazole , rifampicin , drug Subjects donate unit blood within 60 day blood component within 30 day first administration investigational product . Subjects consume excessive alcohol caffeine ; excessively smoke</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>